참고문헌

1. de Vries AC, van Grieken NC, Looman CW, et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology 2008;134:945-952. https://doi.org/10.1053/j.gastro.2008.01.071
2. Kim N, Park RY, Cho SI, et al. Helicobacter pylori infection and development of gastric cancer in Korea: long-term follow-up. J Clin Gastroenterol 2008;42:448-454. https://doi.org/10.1097/MCG.0b013e318046eac3
3. Lee SH, Jang BI. Intestinal metaplasia: reversible after treatment? Korean J Helicobacter Up Gastrointest Res 2013;13:91-94. https://doi.org/10.7704/kjhugr.2013.13.2.91
4. Tsuda M, Asaka M, Kato M, et al. Effect on Helicobacter pylori eradication therapy against gastric cancer in Japan. Helicobacter 2017. doi: 10.1111/hel.12415. [Epub ahead of print]
5. Hwang YJ, Kim N, Yun CY, et al. Predictive factors for improvement of atrophic gastritis and intestinal metaplasia: a long-term prospective clinical study. Korean J Helicobacter Up Gastrointest Res 2018;18:186-197. https://doi.org/10.7704/kjhugr.2018.18.3.186
6. Hwang YJ, Kim N, Lee HS, et al. Reversibility of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication - a prospective study for up to 10 years. Aliment Pharmacol Ther 2018;47:380-390. https://doi.org/10.1111/apt.14424
7. Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy 1969;1:87-97. https://doi.org/10.1055/s-0028-1098086